Stacey M. Stevens
Net Worth

Last updated:

What is Stacey M. Stevens net worth?

The estimated net worth of Ms. Stacey M. Stevens is at least $9,979,018 as of 5 Jan 2022. She owns shares worth $598,406 as insider, has earned $1,138,502 from insider trading and has received compensation worth at least $8,242,110 in iCAD, Inc..

What is the salary of Stacey M. Stevens?

Ms. Stacey M. Stevens salary is $484,830 per year as Pres in iCAD, Inc..

How old is Stacey M. Stevens?

Ms. Stacey M. Stevens is 57 years old, born in 1968.

What stocks does Stacey M. Stevens currently own?

As insider, Ms. Stacey M. Stevens owns shares in one company:

Company Title Shares Price per share Total value
iCAD, Inc. (ICAD) Pres 154,627 $3.87 $598,406

What does iCAD, Inc. do?

iCAD, Inc. provides image analysis, workflow solutions, and radiation therapy for the treatment of cancer in the United States. It operates through two segments, Cancer Detection and Cancer Therapy. The company offers PowerLook platform, which hosts the AI algorithm solutions and manages the communications between imaging acquisition systems, and image storage and review systems; SecondLook, a machine learning-based cancer detection algorithm that analyzes 2D full-field digital mammography images to identify and mark suspicious masses and calcifications; and automated density assessment solutions, which provides automated, consistent, and standardized density assessment. It also offers ProFound AI, a deep-learning algorithm designed to detect malignant soft-tissue densities and calcifications in digital breast tomosynthesis; ProFound AI Risk, a tool that provides breast cancer risk estimation based on a screening mammogram; and magnetic resonance imaging applications, a tool to detect breast and prostate cancer. In addition, the company offers VeraLook, a solution designed to support the detection of colonic polyps in conjunction with CT Colonography. Further, it provides Xoft Axxent electronic brachytherapy systems for the treatment of early stage breast, non-melanoma skin, and gynecological cancers to university research and community hospitals, cancer care clinics, veterinary facilities, and dermatology offices. The company sells its products through direct sales organizations, as well as through various original equipment manufacturer partners, distributors, technology platform partners, and resellers. It also exports its products in Europe, Taiwan, Canada, China, and internationally. The company was formerly known as Howtek, Inc. and changed its name to iCAD, Inc. in June 2002. iCAD, Inc. was incorporated in 1984 and is headquartered in Nashua, New Hampshire.

Stacey M. Stevens insider trading

iCAD, Inc.

Ms. Stacey M. Stevens has made 20 insider trades between 2008-2022, according to the Form 4 filled with the SEC. Most recently she purchased 17,006 units of ICAD stock worth $104,927 on 5 Jan 2022.

The largest trade she's ever made was exercising 33,676 units of ICAD stock on 12 Sep 2008. As of 5 Jan 2022 she still owns at least 154,627 units of ICAD stock.

Transaction Date Security Shares Price per share Total value Source
Purchase
Common Stock 17,006 $6.17 $104,927
Sale
Common Stock 5,000 $17.63 $88,150
Option
Employee Stock Option (right to buy) 235 N/A N/A
Sale
Common Stock 9,402 N/A N/A
Option
Common Stock 8,568 N/A N/A
Sale
Common Stock 20,000 $13 $260,000
Sale
Common Stock 18,665 $11.28 $210,485
Option
Common Stock 18,665 $11.28 $210,485
Option
Employee Stock Option (right to buy) 5,567 N/A N/A
Option
Common Stock 1,100 $6.68 $7,348
Option
Employee Stock Option (right to buy) 1,100 $6.68 $7,348
Sale
Common Stock 1,100 $6.68 $7,348
Sale
Common Stock 15,873 $2.27 $36,032
Option
Employee Stock Option (right to buy) 15,873 $2.27 $36,032
Option
Common Stock 15,873 $2.27 $36,032
Option
Employee Stock Option (right to buy) 24,127 $2.27 $54,768
Option
Common Stock 24,127 $2.27 $54,768
Sale
Common Stock 24,127 $2.27 $54,768
Option
Common Stock 6,667 $2.9 $19,334
Sale
Common Stock 6,667 $2.9 $19,334
Option
Employee Stock Option (right to buy) 6,667 $2.9 $19,334
Sale
Common Stock 10,000 $5.1 $51,000
Option
Employee Stock Option (right to buy) 10,000 $5.1 $51,000
Option
Common Stock 10,000 $5.1 $51,000
Option
Option (right to buy) 27,298 $7.88 $215,026
Option
Common Stock 27,298 $7.88 $215,026
Sale
Common Stock 17,298 $5.75 $99,464
Sale
Common Stock 100 $5.75 $575
Option
Common Stock 100 $5.75 $575
Option
Employee Stock Option (right to buy) 100 $5.75 $575
Option
Common Stock 100 $5.75 $575
Option
Employee Stock Option(right to buy) 100 $5.75 $575
Sale
Common Stock 100 $5.75 $575
Sale
Common Stock 1,700 $10 $17,000
Option
Employee Stock Option (right to buy) 1,700 $10 $17,000
Option
Common Stock 1,700 $10 $17,000
Option
Employee Stock Option (right to buy) 503 $10.01 $5,036
Sale
Common Stock 503 $10.01 $5,036
Option
Common Stock 503 $10.01 $5,036
Option
Common Stock 299 $5.75 $1,719
Option
Employee Stock Option (right to buy) 299 $5.75 $1,719
Sale
Common Stock 299 $5.75 $1,719
Option
Employee Stock Option (right to buy) 10,000 $2.27 $22,700
Option
Common Stock 10,000 $2.27 $22,700
Sale
Common Stock 10,000 $2.27 $22,700
Option
Employee Stock option (Right to buy) 13,333 $2.9 $38,666
Option
Common Stock 13,333 $2.9 $38,666
Sale
Common Stock 13,333 $2.9 $38,666
Sale
Common Stock 10,000 $10.94 $109,350
Sale
Common Stock 5,000 $10.57 $52,850
Option
Common Stock 33,676 $1.7 $57,249
Sale
Common Stock 15,000 $4.23 $63,450
Option
Common Stock 15,000 $1.98 $29,700
Option
Employee Stock Options (Right to buy) 15,000 $1.98 $29,700

iCAD key executives

iCAD, Inc. executives and other stock owners filed with the SEC: